Maximilian Julve
Clinical Assistant Professor Stanford University
Dr. Max Julve is a medical oncologist and Clinical Assistant Professor of Medicine (Oncology) at Stanford University School of Medicine, with a clinical and research focus in solid tumor cellular therapy and melanoma.
Dr. Julve completed his medical training at Barts and The Royal London School of Medicine in the United Kingdom, followed by internal medicine training at teaching hospitals across North and Central London. He was subsequently awarded a National Institute for Health and Care Research (NIHR) Academic Clinical Fellowship in Medical Oncology at Imperial College London. During this time, alongside his clinical training, he conducted translational research within the King’s College London Immunoengineering group, focusing on transcriptional optimization of CAR-T cell therapies.
Dr. Julve later completed advanced clinical fellowships in solid tumor cellular therapy and melanoma at The Royal Marsden Hospital, London, and earned an MD(Res) doctorate investigating the role of immunosuppressive granulocytes in patients receiving immunotherapy.
He is a clinical investigator specializing in melanoma, immuno-oncology, and solid tumor cellular therapy, with a particular emphasis on translating mechanistic insights from the laboratory into novel therapeutic strategies for patients.
Seminars
As the field moves beyond melanoma, the need for optimized efficacy and safety is forcing a rethink of manufacturing strategies and delivery strategies.
This workshop addresses the growing recognition that current TIL strategies involve bulk TIL expansion, diluting tumor reactive potential and requiring high dose IL-2 for efficacy.
Key questions addressed in this workshop:
- Which tumor-infiltrating lymphocyte subsets are truly reactive rather than expanded bystanders?
- Do selection approaches such as PD-1 or neoantigen targeting enrich potency or accelerate exhaustion?
• How can next-generation approaches optimize safety vs. efficacy?
- Comparing genome editing approaches used to enhance potency, persistence, and tumor recognition
- Reviewing safety, manufacturability, and regulatory trade-offs of engineered TIL designs
- Identifying where genetic modification adds clear clinical value vs. added complexity
- Can TIL manufacturing be designed for in vivo development rather than culturing the cells in vitro?
